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Administering Plasmid DNA Encoding Tumor 
Vessel–anchored IFN-α for Localizing Gene  
Product Within or Into Tumors
Ryan Craig1, Jeffry Cutrera1, Shiguo Zhu1, Xueqing Xia1, Yong-Hwan Lee2 and Shulin Li1
1Department of Comparative Biomedical Sciences, Louisiana State University, Baton Rouge, Louisiana, USA; 2Department of Biological Sciences, 
Louisiana State University, Baton Rouge, Louisiana, USA
Tumor-targeted gene delivery has been intensively 
studied in the field of gene therapy, but no attention has 
been given to targeting the therapeutic gene products, 
which are transcribed and translated from the injected 
genes, into tumors. Targeting immune stimulatory gene 
products into tumors is the key to triggering tumor- 
specific CD8+ T-cell responses and reducing systemic 
toxicity. To target the gene products generated from the 
injected genes into tumors, genes encoding the tumor-
targeted fusion gene product were generated and 
administered locally and systemically via electropora-
tion. As anticipated, administration of a therapeutic gene 
encoding IFN-α and the tumor vessel–targeted peptide 
CDGRC fusion gene product minimizes the leakage of 
immunostimulatory cytokine from tumors into the blood 
circulation, increases the infiltration of CD8+ T cells into 
tumors, induces a high magnitude of cytotoxic T-cell 
lysis (CTL) activity, and reduces tumor vessel density. As 
a result, tumor growth was more significantly inhibited 
by administering the IFN-α-CDGRC gene than by admin-
istering the wild-type IFN-α gene. The same result was 
obtained with the systemic administration of the tumor-
targeted IFN-α gene. This gene product–based tumor-
targeted gene therapy approach could complement any 
other tumor-targeted gene delivery method for improv-
ing tumor-targeting efficiency.
Received 16 October 2007; accepted 14 February 2008; published 
online 18 March 2008. doi:10.1038/mt.2008.40
INTRODUCTION
One of the most daunting tasks facing the field of cancer therapy 
today is finding an effective means of transporting therapeutic 
agents to the site of tumors. The most attractive method would 
be targeting cell surface proteins that are altered on cancer cells or 
in the tumor vasculature. These proteins could be growth factor 
receptors,1 cell adhesion molecules,2 integrins,3 or other surface 
markers on endothelial cells.
One of the current interests in the field of cancer research lies 
in targeting the tumor vasculature, including tumor blood and 
lymphatic vessels.4 Endothelial cells line blood vessels and serve as 
“gateways” to tumor cells. They contain surface proteins that func-
tion as vascular receptors able to transduce growth or angiogenic 
signals.2 The main advantage of targeting endothelial cells is that 
they are highly accessible from the blood stream, thus simplifying 
the experimental design.
Several peptides express high affinity for endothelial markers, 
such as RGD-4C (ACDCRGDCFCG) for integrins5 or CNGRC 
for aminopeptidase N/CD13.2 Of the 25 known integrins, eight 
bind to peptides containing the sequence RGD, which serves as 
the main integrin recognition site in extracellular matrix proteins.6 
The RGD-4C peptide shows high affinity for αvβ5 and αvβ3 inte-
grins.7 Integrin αvβ3 is highly expressed in endothelial cells of 
angiogenic vessels and exhibits high affinity for matrix metallo-
proteinase-2.8 The αvβ3 receptor binds to a wide range of ligands 
including, but not limited to, fibronectin, vitronectin, osteopontin, 
and fibrinogen.9
The specificity of the sequence RGD-4C for αvβ5 and αvβ3 inte-
grins makes this peptide a competitive candidate for targeting 
DNA vectors to the tumor vasculature. In fact, this peptide has 
been integrated as part of adenovirus surface proteins and has 
been heavily explored for targeting the virus into αvβ3 express-
ing endothelial and tumor cells via the RGD-4C–αvβ3 interac-
tion, instead of using the natural coxsackievirus and adenovirus 
receptors that are often lost in highly malignant tumor cells.10 
Curnis et al. showed that coupling tumor necrosis factor-α with 
αvβ3 ligands improves its antiangiogenic activity.
11 They reported 
that subnanogram doses are enough to induce antitumor effects 
when tumor necrosis factor is fused with ACDCRGDCFCG 
(RGD-4C) and coadministered with chemotherapeutic drugs 
like melphalan. de Groot et al. developed a doxorubicin pro-
drug conjugated to RGD-4C for reducing the systemic toxicity 
of doxorubicin.12
Interferon (IFN)-α has been shown to inhibit tumor growth 
by enhancing the antitumor immune response,13 preventing 
angiogenesis in the tumor vasculature,14 and inducing apoptosis 
of tumor cells.15 It is effective in treating several cancers includ-
ing renal cell carcinoma,16 hairy cell leukemia,17 malignant 
melanoma,18 basal cell carcinoma,19 squamous cell carcinoma 
of the head and neck,20 and multiple myelomas.21 However, 
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IFN-α protein therapy is toxic and expensive.22,23 A high level 
of IFN-α protein in the tumor is required for maximizing the 
therapeutic efficacy.24
To reduce the cost and increase the accumulation of IFN-α 
in tumors, we have generated a fusion gene encoding IFN-α and 
CDGRC peptide (IFNα-CDGRC). Administration of this fusion 
gene via intratumoral electroporation enhances anchorage of the 
fusion gene product into tumors and significantly improves the 
therapeutic efficacy. As far as we know, this is the first report of 
using a gene therapy approach to simultaneously express and 
target the gene product into tumors for increasing the accumula-
tion of the gene product in the tumors and enhancing antitumor 
efficacy via either local or distant tumor delivery.
RESULTS
CDGRC, CNGRC, and RGD-4C containing reporter 
gene products illustrate similar tumor 
anchorage activity
Most tumor-targeted strategies have been used for systemic gene 
or vector delivery, but the study described here aims to anchor 
the tumor vessel–targeted gene product from the intratumoral 
injected IFNα-CDGRC gene at the tumor sites. The purpose of this 
strategy is to prevent the leakage of the therapeutic gene product 
from the injected tumor sites into blood circulation, thus increas-
ing the accumulation of IFN-α in local tumors. An increased level 
of IFN-α and interleukin-12 in the tumor is required for maximiz-
ing the therapeutic efficacy.25,26
To yield a tumor vessel–anchored gene product, three rep-
orter fusion genes encoding secreted alkaline phosphatase 
(SEAP) and tumor vessel–anchored peptides, CDGRC, CNGRC, 
and CDCRGDCFC (RGD-4C), were generated (Figure 1a). 
The selection of mini peptides, instead of a large antibody, 
for anchoring the therapeutic gene product may reduce the 
 concern about immunogenicity. Also, the selected CDGRC 
shares its homology with both the core tumor vessel–targeted 
peptide, RGD-4C, and the other well-characterized tumor- 
targeted peptide, CNGRC.27–29 To test whether the tumor-
anchorage activity levels of SEAP gene products using RGD-4C, 
CDGRC, and CNGRC peptides were comparable, the expres-
sion of SEAP was determined in the liver, spleen, lung, heart, 
and tumors, and the expression indexes between tumors and 
 livers and between tumors and overall tissues were determined. 
As expected, the SEAP activities were primarily detected in 
tumors as illustrated by the large ratios between tumors and 
tissues with no significant difference among the three tested 
 peptides (Figure 1b and c).
It is known that DGR-containing peptides bind to the tumor 
vessel integrin αvβ3 (ref. 30). This binding is made by a strong salt 
bridge formed between Arg (R) of the peptide and the negatively 
charged residues in the integrin. Although the continued high 
negative potential in the ligand Asp (D) binding site may cause 
a negative effect on this peptide binding, this pocket is occu-
pied by Mn++. As a result, the ligand Asp is in direct contact 
with this metal ion, providing an additional salt bridge and, ulti-
mately, enhancing binding of the peptide (Figure 1e). If Asn (N) 
is in the ligand, as in NGR, instead of Asp (D), the salt bridge 
between Asn and Mn++ may not be formed, resulting in a signifi-
cant loss in binding force. Thus, NGR cannot effectively bind to 
the integrin due to the missing interaction between Mn++ and 
the Asp in the peptide ligand.
Next, we examined whether CDGRC binds to CD13, the 
receptor for CNGRC.28 To determine the binding activity of 
CDGRC to CD13, a cell-binding competition assay was per-
formed between reporter gene products (SEAP-CDGRC, SEAP-
CNGRC, and SEAP) and the anti-CD13 antibody in a murine 
endothelial cell line (EC40). This strategy was chosen because 
antibodies in general have a very high–binding affinity com-
pared to other competitor molecules, and illustration of any 
competition from the high-affinity antibody binding by these 
mini peptide–containing SEAP gene products would be a strong 
indicator that this peptide binds to the target CD13 receptor. 
Indeed, SEAP-CDGRC illustrates a similar level of inhibition 
on the anti-CD13 antibody-mediated binding to the endothe-
lial cells as CNGRC-SEAP (Figure 1d). This result is a clear 
 indication that the CDGRC not only binds αvβ3 as found by 
the other group30 but also binds as effectively as CNGRC to the 
CD13 (Figure 1d).
The dual binding activity by the CDGRC illustrated above 
provided the basis for selecting this peptide encoding sequence to 
generate a CDGRC and IFN-α-encoding fusion gene (Figure 2a). 
To determine whether the fusion therapeutic gene product is able 
to anchor to tumors, the expression levels of IFN-α and tumor-
anchored IFNα-CDGRC in tumors and blood were determined 
after intratumoral administration of the genes via electropora-
tion. The expression index between tumors and blood illustrates 
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Figure 1 Tumor vessel–anchored binding activity from fusion gene 
products and targeted peptides. (a) Structures of wild-type and tumor 
vessel–anchored secreted alkaline phosphatase (SEAP) reporter genes 
encoding SEAP and CDGRC, CNGRC, or RGD-4C. (b) The ratio of SEAP 
expression between tumors and a combination of livers, spleens, and 
hearts. (c) The ratio of SEAP expression between tumors and livers. 
(d) Inhibition of anti-CD13 antibody binding to endothelial cells (EC40) 
with tumor vessel-anchored gene product. (e) Structural analysis of DGR 
peptide–binding activity using the known crystal structure of the integrin 
αvβ3. The ligand peptide and Mn
++ ion are shown as a stick model and a 
ball, respectively, with color-coded atoms: red, oxygen; blue, nitrogen; 
yellow, carbon; and cyan, Mn++. The ligand binding site in the integrin 
complex is represented as a surface diagram with color-coded surface 
electropotentials: red, negative; blue, positive; and white, neutral. CMV, 
cytomegalovirus.
Molecular Therapy  vol. 16 no. 5 may 2008 903
© The American Society of Gene Therapy
Gene Product Tumor Auto-targeted Gene Therapy
IFNα-CDGRC is more effective than wild-type IFN-α 
in reducing tumor vessel density and inducing CD8+ 
T–cell immune response
IFN-α plays multiple roles in the inhibition of tumor growth, 
including the induction of antitumor immune response,13 inhibi-
tion of angiogenesis in the tumor vasculature,14 and enhancement 
of tumor-cell apoptosis.15 These effects by tumor vessel–anchored 
IFNα-CDGRC gene therapy and wild-type IFN-α gene therapy 
were compared in SCCVII tumors.
Intratumoral administration of plasmid DNA encoding tumor 
vessel–anchored IFNα-CDGRC reduces vessel density by 40%, 
and administration of the wild-type IFN-α gene reduces the vessel 
density by 13% (Figure 3a), which shows threefold more inhibi-
tion achieved by the tumor vessel–anchored IFNα-CDGRC gene 
therapy than wild-type IFN-α gene therapy (P = 0.00017). In fact, 
large necrosis areas were found in all tumors receiving tumor 
 vessel–anchored IFNα-CDGRC gene therapy, but were found only 
in ~25% of tumors receiving wild-type IFN-α gene therapy. This 
necrosis by tumor vessel–anchored IFNα-CDGRC gene therapy 
may be partially caused by inhibition of tumor vessel development 
and partially caused by an enhanced cell death because the terminal 
uridine deoxynucleotidyl transferase dUTP nick end labeling assay 
results illustrated a larger area of apoptosis by IFNα-CDGRC than 
wild-type IFN-α gene therapy (data not shown).
To illustrate the antitumor immune response, the infiltration of 
both CD4+ and CD8+ T cells into tumors was compared between 
tumor vessel–anchored IFNα-CDGRC and wild-type IFN-α gene 
therapy. Tumor vessel–anchored IFN-α gene therapy was found to 
be three times more effective than wild-type IFN-α gene therapy 
in inducing infiltration of CD8+ T cells (P = 0.042), but no differ-
ence was detected in the infiltration of CD4+ T cells between these 
treatment groups (Figure 3c).
To determine whether tumor vessel–anchored IFNα-CDGRC 
gene therapy induces a higher level of cytotoxic T-cell lysis (CTL) 
activity than wild-type IFN-α gene therapy, CTL activity was 
compared in mice that received two types of therapeutic genes. 
As expected, tumor vessel–anchored IFNα-CDGRC gene therapy 
induces ~20–30% higher levels of CTL activity than wild-type 
IFN-α gene therapy (Figure 3d). 
Tumor vessel–anchored IFN-α gene therapy is more 
effective in inhibition of tumor growth than 
wild-type IFN-α gene therapy
To examine the therapeutic efficacy, tumor volumes were mea-
sured following the administration of tumor vessel–anchored 
IFNα-CDGRC and wild-type IFN-α encoding genes. CDGRC 
alone was omitted in the treatment groups because the maximum 
level of IFNα-CDGRC protein was between 6 and 8 ng/mg protein 
in tumor tissues and this level of CDGRC was found to have no 
effect on tumor growth inhibition in our preliminary study (as 
determined by administering the reporter fusion gene encoding 
SEAP and SEAP-CDGRC) (data not shown).
An increased inhibition of tumor growth was detected by 
administration of the tumor vessel–anchored gene in two indepen-
dent studies (Figure 4a and b; P < 0.05). The true tumor volume 
reduction by tumor vessel–anchored gene therapy may actually 
be more significant than the tumor volume shown in Figure 4 
because all tumors using this tumor-anchored gene therapy con-
tain necrotic areas, but the tumor volume measurement is based on 








































Figure 2 Expression of tumor-anchored IFNα-CDGRC via administra-
tion of plasmid DNA encoding IFN-α and the tumor vessel–anchored 
mini peptide, CDGRC. (a) Structure of wild-type IFN-α gene (pIFNα) 
and the tumor vessel–anchored IFN-α gene (pIFNα-CDGRC). (b) The 
expression ratio of IFN-α and tumor vessel–anchored IFN-α between 
tumors and blood. Plasmid DNA encoding IFN-α, IFN-α-CDGRC, or 
no transgene was administered into SCCVII tumors via electroporation 
(20 µg/tumor, n = 4) at the indicated electroporation parameters 
(see Materials and Methods). Tumors and blood were collected for 
























































































































Figure 3 Inhibition of tumor vessel density and enhancement of 
CD8+ T-cell infiltration by administering IFNα-CDGRC over wild-type 
IFN-α. Plasmid DNA encoding wild-type IFN-α (pIFNα), tumor vessel–
anchored IFNα-CDGRC (pIFNα-CDGRC), and no transgene (pCtrl), 
respectively, was administered into SCCVII tumors (20 µg/mouse) via 
electroporation. Ten days after one treatment, tumors were collected, 
sectioned, and immunostained with anti-CD31, -CD8, and -CD4 
antibodies (n = 9). Five days after the second treatment (n = 5), spleens 
were collected for determining the cytotoxic T-cell lysis (CTL) activity 
against tumor cells in the presence of anti-NK antibody for avoiding 
detection of any NK cell–mediated tumor-cell death. (a) Tumor vessel 
density from different treatment groups (P = 0.00017 for pIFNα versus 
pIFNα-CDGRC). (b) Infiltration of CD8+ T cells from different treatment 
groups (P = 0.042 for pIFNα versus pIFNα-CDGRC). (c) Infiltration of 
CD4+ T cells from two treatment groups. (d) CTL activity in the two treat-
ment groups (P = 0.0057). CMV, cytomegalovirus; IFN-α, interferon-α; 
NK cell, natural killer cell.
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Tumor vessel–targeted IFN-α gene therapy is also 
effective when delivered systemically
To determine whether the IFNα-CDGRC gene therapy dem-
onstrates a stronger antitumor efficacy when it is administered 
systemically, both wild-type IFN-α and IFNα-CDGRC were 
administered into hindlimb muscles or skin via electroporation 
in a colon tumor–bearing model. Administration to muscles 
or skin was counted as systemic delivery because the injected 
tissues are distal from tumors and the gene products made from 
the injected tissues were secreted into blood circulation. After 
administration, inhibition levels of tumor growth and antitumor 
CTL activity were compared. Increased inhibition of tumor 
growth and increased CTL activity are the ultimate surrogate 
end points for the enhanced IFN-α accumulation because tumor- 
specific accumulation of immune stimulatory cytokines is the key 
to inducing effective antitumor response and CTL activity.24–26 As 
is also found from intratumoral administration, IFNα-CDGRC 
yields a much better tumor growth inhibition from systemic 
delivery than the wild-type IFN-α (Figure 5a). Likewise, IFNα-
CDGRC induces much stronger CTL activity than wild-type IFN-α 
with this systemic delivery (Figure 5b). These results illustrate 
that tumor-targeted IFNα-CDGRC gene therapy is beneficial for 
treating tumors with both systemic and local administrations.
DISCUSSION
The major goal of this study was to determine whether admin-
istering IFN-α gene encoding the tumor-targeted IFN-α gene 
 product (IFNα-CDGRC) into tumors via intratumoral electro-
poration would increase the therapeutic efficacy and improve 
the antitumor immune response. Our results support the tumor-
anchoring assumption because a fourfold higher level of IFNα-
CDGRC was accumulated in tumors compared to wild-type 
IFN-α, in two independent experiments (Figure 1). Because this 
 tumor-anchoring approach occurs after protein translation and 
protein secretion outside of cells, it can complement other tumor-
targeted gene delivery approaches occurring at the delivery and 
transcriptional levels to achieve double or triple tumor-targeting 
effects. For example, this anchoring strategy complements the 
tumor-targeted electroporation injection for accumulating the 
therapeutic cytokine product IFNα-CDGRC at the injected tumors 
(Figure 1). Associated with this accumulation, a significant infil-
tration of CD8+ T cells and inhibition of tumor angiogenesis were 
achieved by administering this IFNα-CDGRC gene, compared to 
administering the wild-type IFN-α gene (Figure 3).
As was found from local tumor delivery, systemic adminis-
tration of tumor-targeted IFNα-CDGRC also enhances tumor 
growth inhibition and tumor-specific CTL activity (Figure 5). 
These results suggest that this tumor-targeted gene therapy not 
only can complement other tumor targeted delivery approaches 
for enhancing antitumor efficacy but also works independently 
for enhancing antitumor efficacy. In summary, the local tumor 
and distal administration results support the assumption that 
 accumulation of immune stimulatory cytokines into tumor is the 
key to triggering a significant antitumor response. This notion 
was also found to be true for interleukin-12-mediated antitumor 
efficacy.25,26 The results from this study and the interleukin-12 
administration route study conducted previously suggest that 
different immune stimulatory cytokines may share the same 
 principal,25,26 which is that tumor-specific accumulation of these 
cytokines boost tumor-specific antitumor immune response.
Unlike antibody- or peptide-mediated recombinant cytokine 
protein tumor targeting,31,32 this study uses a gene therapy 
approach to express the tumor-anchored gene product containing 
a mini-CDGRC peptide and IFN-α. This peptide shares the identi-
cal RGD-4C core sequence (Figure 1) and also has a high homol-
ogy with the mini-tumor vessel–targeted peptide CNGRC that 
binds aminopeptidase N.2 The structure of amino acids “D” and 
“N” that appear in CDGRC and CNGRC, respectively, is almost 
identical, which suggests that the CDGRC peptide not only binds 
the integrin αvβ3 (ref. 30) but also aminopeptidase N.
28 Indeed, the 
competition study demonstrates that CDGRC-SEAP is as effective 
as CNGRC-SEAP in inhibiting the binding of the high-affinity 
anti-CD13 antibody (5 µg total antibody) (Figure 1d). However, 
CNGRC does not bind αvβ3 favorably despite its similarity to 
CDGRC, according to the structural analysis (Figure 1e).
A cyclic peptide, CDGRC, was used because a cyclic structure is 
more effective than linear NGR motifs in receptor:ligand binding.33 
This short peptide, containing only five amino acids, has much less 
chance to induce immunogenicity than a large polypeptide as deter-
mined from the CNGRC study.34 Therefore, this strategy has great 
potential for anchoring the gene product in tumors without trigger-
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Figure 4 Comparison of tumor growth inhibition between pIFNα-
CDGRC versus pIFNα gene therapy via local tumor administration. 
SCCVII tumor-bearing mice (n = 4) were treated with 20 µg of pCtrl 
(control), pIFNα, and pIFNα-CDGRC plasmid DNA in a volume of 30 µl 
saline via intratumoral administration and electroporation. (a,b) Two 
administrations were performed at 10 days apart. Two independent 
experiments were performed. IFN-α, interferon-α.
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Figure 5 Comparison of tumor growth inhibition and tumor-specific 
CTL activity between systemic expression of tumor-anchored IFNα-
CDGRC and wild-type IFN-α. DNA was injected into skins (the first 
administration) and muscles (the second administration) located distant 
from tumors (n = 6). Two administrations were performed at 10 days 
apart at a dose of 10 µg/mouse in a volume of 30 µl saline. (a) Inhibition 
of tumor growth after systemic expression of IFN-α and tumor-anchored 
IFNα-CDGRC. (b) Tumor-specific CTL activities following expression of 
two types of IFN-α. Spleen cells were isolated for CTL activity assay 7 
days after the second administration. CTL, cytotoxic T-cell lysis; IFN-α, 
interferon-α.
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Others have demonstrated that the CNGRC-TNFα conju-
gated protein is more effective in treating tumors than the wild-
type tumor necrosis factor-α at a low dose.35 This observation may 
apply to gene therapy as illustrated in this study, in which tumor-
anchored IFNα-CDGRC gene therapy is more effective than wild-
type IFN-α gene therapy for treating tumors. The advantage of the 
electroporation gene therapy approach is that it is easier and less 
expensive than recombinant protein therapy. From an economic 
point of view, this gene therapy strategy has great potential.
MATERIALS AND METHODS
Gene constructs encoding tumor vessel–anchored reporter gene products 
and therapeutic gene product. SEAP gene constructs encoding fusion 
protein SEAP and tumor vessel–targeted peptides CDGRC, CNGRC, 
or RGD-4C were generated via direct PCR. The same forward primer 
5ʹ-GCATCATCCCAGTTGAGGAG-ʹ was used for generating fusion genes 
SEAP-CDGRC, SEAP-CNGRC, and SEAP-RGD-4C. The reverse prim-
ers were 5ʹ-GTAGGATCCTTATCAGCATCTTCCATCGCATGTCTGC 
TCGAAGCGGCCGGC-3ʹ for generating SEAP-CDGRC fusion gene, 5ʹ-
TTATCAACAACGACCGTTACATGTCTGCTCGAAGCGGCCGG-3ʹ 
for generating SEAP-CNGRC fusion gene, and 5ʹ-TTATCAGCAGAA
ACAATCACCGCGGCAATCACA-3ʹ for generating SEAP-RGD-4C 
fusion gene. The PCR product was cloned into pCR2.1 TA cloning vector 
(Invitrogen, Carlsbad, CA), and then subcloned into a vector containing 
a cytomegalovirus promoter, a mini-intron, wild-type SEAP gene, and a 
human growth hormone polyadenylation signal using restriction enzymes 
BamH1 and SpeI (Figure 1). The sequence was confirmed by sequence 
analysis and reporter gene activity assay.
Using the same strategy, IFNα-CDGRC encoding gene construct was 
generated (Figure 2). In brief, the forward and reverse primers used for 
generating DNA fragment encoding IFNα-CDGRC were 5ʹ-GTAAGC 
TTATGGCTAGGCTCTGTGCTTTCC-3ʹ and 5ʹ-TCAGCATCTTCCAT 
CGCACTCCTTCTCCTCACTCAGTCT-3ʹ. The PCR product containing 
IFNα-CDGRC encoding sequence was cloned into pCR2.1 TA cloning 
vector. The IFNα-CNGRC fusion gene was released from this vector with 
HindIII and SpeI restriction digestion enzymes and subcloned into an 
expression vector cut with HindIII and SpeI. The expression vector for this 
fusion gene is the same as the one expressing the wild-type IFN-α (Figure 2). 
The fusion gene sequence was confirmed by sequence analysis.
Tumor models and DNA delivery via electroporation. Six- to eight-week-
old female C3H/HeN or Balb/c mice, weighing 18–20 g, from the in-house 
 animal breeding facility were used for this study and were maintained under 
National Institutes of Health guidelines, approved by the Institutional 
Animal Care and Use Committee of Louisiana State University.
SCCVII and CT26 cell lines were maintained in Dulbecco’s modified 
Eagle’s medium containing 10% fetal bovine serum (Life Technologies, 
Rockville, MD). SCCVII and CT26 tumors were generated by sub-
cutaneously inoculating the mice with 2 × 105 tumor cells in a 30-µl 
volume into C3H and Balb/c mice, respectively. Tumor dimensions were 
measured with calipers, and volumes were calculated from the formula: 
V = (π/8)(a × b2), where V = tumor volume, a = maximum tumor diameter, 
and b = diameter at 90° to “a”.36 Using the protocols described previously, 
plasmid DNA was injected into tumors, skins and muscles. Each injection 
was followed by immediate electroporation.37,38 The parameters for 
intratumoral electroporation were previously set at 450 V/cm and 20 ms 
pulse duration for 2 pulses.37 The parameters for intramuscular and 
intradermal electroporation were 350 V/cm, 20 ms pulse duration for 2 
pulses.39 The endotoxic free plasmid DNA was prepared using Qiagen 
Endotoxic free plasmid DNA preparation kit (Germantown, MD).
Gene expression analysis. In brief, tumors were injected with plasmids 
that expressed SEAP-CDGRC, SEAP-CNGRC, or SEAP-RGD-4C with a 
syringe followed by electroporation. After 1 day, the tumors and organs 
were harvested, sectioned at 10 µm, and the expression of reporter genes 
was measured using a SEAP activity assay kit (Tropix, Bedford, MA). 
Using the same administration approach, plasmid DNA encoding IFN-α 
and IFNα-CDGRC was administered and the level of IFN-α was detected 
using a kit from PBL Biomedical Laboratories (Piscataway, NJ).
Fluorescent microscope-based CTL assay. Cytotoxic T-lymphocyte (CTL) 
activity was evaluated using a CyToxiLux kit (OncoImmunin, Gaithersburg, 
MD), a single–cell–based fluorogenic cytotoxicity assay.40 Splenocytes were 
obtained from SCCVII tumor-bearing C3H mice 2 weeks after treatment. 
These splenocytes are referred to as effector cells. The effector cells were 
primed by coculture with mitomycin C–treated SCCVII tumor cells in a 
ratio of 25:1 for 5 days in Rosewell Park Memorial Institute-1640 medium 
with 20% fetal calf serum. Effector cells were incubated with red fluores-
cence–labeled target SCCVII cells in the indicated ratios in a volume of 
200 µl for 16 hours. The apoptotic target cells (red/yellow colored cells) 
were examined using an Olympus BX41 fluorescence microscope. CTL 
activity was calculated using the equation: percentage specific killing = 
100 × (apoptotic target cells − spontaneous apoptotic target cells)/(total 
target cells).
Immunostaining of T-cell infiltration. The procedures for frozen-block 
preparation, tissue sectioning, and immunostaining were the same as 
described previously.37–39,41 The primary antibody applied to the sections 
was anti-CD8 (1:400; Santa Cruz Biotechnology, Santa Cruz, CA). 
Flow cytometric analysis of CD13 expression. EC40 (American Type 
Culture collection, Manassas, VA) cells were stained with phycoerythrin-
labeled anti-CD13 receptor antibody (BD Biosciences, San Jose, CA) in the 
presence of tumor lysates containing 50 ng protein of SEAP, SEAP-CDGRC, 
or SEAP-CNGRC. The stained cells were analyzed using FACscan cytom-
eter (BD Biosciences, San Jose, CA). A total of 10,000 cells/sample were 
acquired and data samples were analyzed using Cellquest software.
Structural binding analysis. The binding activity of DGR and NGR to 
the known RGD-binding integrin αvβ3 was analyzed. The coordinates for 
the RGD peptide and αvβ3 integrin were obtained from the pdb “1L5G”.
42 
Protein surface electropotential was calculated using apbs-0.5.1 (ref. 43) and 
the protein surface diagram and the ligand stick model were drawn using 
PyMol Molecular Graphics System (DeLano Scientific, San Carlos, CA).
Statistical analysis. Tumor volume, CD8+ T-cell infiltration, and vessel 
density were the primary outcomes measured. We used the two-sided 
Student’s t-test to compare individual treatments. P values <0.05 were con-
sidered statistically significant.
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